Lecozotan (SRA-333) is a potent and selective 5-HT antagonist developed for Alzheimer's disease treatment. This compound significantly increases the release of glutamate and acetylcholine in the hippocampus and dentate gyrus areas upon potassium ion stimulation, exhibiting cognitive enhancement properties. Long-term use of Lecozotan does not lead to tolerance or dysfunction of the 5-HT(1A) receptor, demonstrating its stable pharmacological properties. Additionally, acute administration can improve learning and memory abilities in rats without affecting their anxiety levels or behavior depression.